Apatinib Plus Camrelizumab Combined With Docetaxel and S1 in First-line Treatment for Metastatic Gastric Cancer

NCT04781686 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

35

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Gastric Adenocarcinoma
Metastatic Gastroesophageal Junction Adenocarcinoma

Interventions

DRUG: Camrelizumab
DRUG: Apatinib Mesylate
DRUG: S1
DRUG: Docetaxel injection

Sponsor

Zhou Fuxiang

Collaborators

[object Object]
[object Object]
[object Object]